文献速递胸部肿瘤放疗放疗物理与技术

非小细胞肺癌术后心脏剂量与总生存的影响因素

Factors impacting cardiac dose and overall survival in post-operative non-small cell lung cancer patients.
PubMed 文献 · Radiother Oncol · 2025-08-23

本研究纳入155例接受术后放疗的N2期非小细胞肺癌患者,采用Cox比例风险模型和弹性网生存回归分析总生存及心脏剂量影响因素。多变量分析显示心脏剂量学变量对总生存无显著影响,总生存主要由内靶区/肺容积比决定,心脏剂量随肿瘤体积和心包淋巴结站受累增加而升高。

要点

  • 心脏剂量学变量在多变量分析中未显著影响总生存。
  • 内靶区/肺容积比是总生存的最重要决定因素。
  • 肿瘤体积增大及心包淋巴结站受累增加心脏剂量。

核心结论

  • 心脏剂量学变量在多变量分析中未对总生存产生显著影响。
  • 总生存主要由内靶区/肺容积比决定。
  • 心脏剂量随肿瘤体积增大、心包淋巴结站受累数目增加和/或肺门淋巴结治疗而直接增加。

研究设计与样本

  • 回顾性队列研究,纳入155例接受术后放疗的N2期非小细胞肺癌患者。
  • 采用Cox比例风险检验分析总生存与广泛临床变量。
  • 采用弹性网生存回归进行多变量分析,贝叶斯方法调参,并进行变量重要性分析。

主要发现

  • 内靶区/肺容积比是最重要的变量,放化疗顺序作用较小。
  • 心脏剂量随肿瘤体积增大和心包淋巴结站(4R/L和/或7-12站)受累而显著增加。
  • 纳入上述因素后,无心脏剂量学变量保持显著。

临床怎么用

  • 术后放疗决策中应重视内靶区/肺容积比等肿瘤负荷因素对总生存的影响。
  • 心脏剂量随肿瘤体积和心包淋巴结站受累增加而升高,计划设计时需关注。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The LungART trial randomized NSCLC patients with N2 disease to adjuvant chemotherapy ± radiotherapy. They found that patients who received radiotherapy had reduced overall survival and claimed that heart dose was the etiological factor, though without offering proof. Consequently, we evaluated cardiac dose and overall survival (OS) in a large cohort of patients treated with adjuvant radiotherapy for N2 disease. METHODS: 155 patients comprised the final cohort, all treated for N2 disease. Cox proportional hazards testing for OS was performed across a wide range of clinical variables. Additionally, we evaluated factors that impacted cardiac dose. We performed multivariable analysis (MVA) using elastic net survival regression. We tuned the model's hyperparameters with Bayesian methods and conducted a variable importance analysis on the resultant model. Lastly, we analyzed relevant features after correcting for multiple comparisons. RESULTS: The internal target volume (ITV)/lung volume ratio was overwhelmingly the most important variable, although chemoradiotherapy sequencing played a small role. Cardiac dose significantly increased with increasing tumor volume and involvement of "peri-cardial" lymph node stations (4R/L and/or stations 7-12). After incorporating these factors, no cardiac dosimetric variables remained significant. CONCLUSION: Cardiac dosimetric variables did not impact upon OS in MVA. OS was overwhelmingly determined by the ITV/lung ratio. Furthermore, increasing cardiac dose was directly impacted by increasing tumor volume, number of "pericardial" lymph node stations involved, and/or treatment of hilar lymph nodes, all of which are eponymous for increasing tumor stage.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Cruz-Chamorro R, Bryant JM, Henning J, et al. Factors impacting cardiac dose and overall survival in post-operative non-small cell lung cancer patients. Radiother Oncol. 2025. PMID: 40854381. doi:10.1016/j.radonc.2025.111117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。